AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC
Trial Parameters
Brief Summary
A prospective, single-arm, exploratory phase II clinical study evaluating the efficacy of Gemcitabine and Nab-palitaxe combined with Cadonilimab sequential short-course radiotherapy in the treatment of patients with locally advanced pancreatic ductal adenocarcinoma.
Eligibility Criteria
Inclusion Criteria: Patients eligible for this study must meet all of the following criteria: 1. Obtain written informed consent before implementing any trial-related procedures; 2. Age ≥ 18 years and ≤ 75 years, gender not specified; 3. Pancreatic cancer confirmed by histopathology examination; 4. Locally advanced pancreatic ductal adenocarcinoma and no prior anti-tumor treatment (radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.) received; 5. At least one measurable lesion on imaging according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). 6. ECOG score 0-1; 7. Expected survival time \>3 months; 8. Adequate organ function, subjects must meet the following laboratory criteria: 1)Absolute neutrophil count (ANC) ≥1.5x10\^9/L without the use of granulocyte colony-stimulating factor in the past 14 days. 2)Platelet count ≥100x10\^9/L without blood transfusion in the past 14 days. 3)Hemoglobin \> 9g/dL without blood transfusion or use of erythropoietin in the